Team explores diabetes drug’s ability to treat RSV infection

Vanderbilt News

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.
The findings were reported in the Journal of Allergy and Clinical Immunology
Liraglutide is one of six “GLP-1R agonists” approved to treat type 2 diabetes. These drugs enhance insulin secretion from the pancreas by activating the glucagon-like peptide 1 receptor (GLP-1R).

Read More

click
tracking
Share
Share